| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 2. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 3. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | ALA1156829 | cell-based format | Novartis Malaria Screening | |
| 4. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | ALA1156829 | assay format | Novartis Malaria Screening | ||
| 5. | ALA4303810 | F | Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) | Homo sapiens | 1,629 | ALA4303122 | organism-based format | SARS-CoV-2 Screening Data 2020-21 |
The page will load shortly, Thanks for your patience!